Vir Biotechnology (VIR) Capital Expenditures (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Capital Expenditures data on file, last reported at $390000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 76.06% year-over-year to $390000.0; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (down 49.09% YoY), and the FY2025 full-year result was $4.8 million, down 33.82% from the prior year.
• Capital Expenditures grew to $390000.0 in Q1 2026, from $348000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $20.6 million in Q2 2022 to a low of $317000.0 in Q3 2025.
• A 5-year average of $6.0 million and a median of $2.5 million in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures surged 4090.74% in 2022 and sank 92.96% in 2024, its largest moves.
• Tracing VIR's Capital Expenditures over 5 years: stood at $12.6 million in 2022, then sank by 87.79% to $1.5 million in 2023, then advanced by 29.97% to $2.0 million in 2024, then plunged by 82.56% to $348000.0 in 2025, then increased by 12.07% to $390000.0 in 2026.
• Business Quant data shows VIR's Capital Expenditures at $390000.0 in Q1 2026, $348000.0 in Q4 2025, and $317000.0 in Q3 2025.